Evidence map›Paper›PMID 31831374›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2020

Brain imaging measurements of fibrillar amyloid-β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ε4 allele.

Valentina Ghisays, Dhruman D Goradia, Hillary Protas, Robert J Bauer, Vivek Devadas, Pierre N Tariot, Val J Lowe, David S Knopman, Ronald C Petersen, Clifford R Jack and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Apolipoprotein E and Alzheimer's disease pathology in a diverse autopsy study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Article
  4. Article
  5. Impact of APOE4-related dementia risk in underrepresented groups from the All of Us research program.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  15. Article
  16. Article
  17. Clinical validity of increased cortical uptake of [European journal of nuclear medicine and molecular imaging · 2021
    Review
  18. Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Valentina GhisaysBanner Alzheimer's Institute, Phoenix, AZ, USA.
Dhruman D GoradiaBanner Alzheimer's Institute, Phoenix, AZ, USA.
Hillary ProtasBanner Alzheimer's Institute, Phoenix, AZ, USA.
Robert J BauerBanner Alzheimer's Institute, Phoenix, AZ, USA.
Vivek DevadasBanner Alzheimer's Institute, Phoenix, AZ, USA.
Pierre N TariotBanner Alzheimer's Institute, Phoenix, AZ, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ronald C PetersenDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Richard J CaselliArizona Alzheimer's Consortium, Phoenix, AZ, USA.
Yi SuBanner Alzheimer's Institute, Phoenix, AZ, USA.
Kewei ChenBanner Alzheimer's Institute, Phoenix, AZ, USA.
Eric M ReimanBanner Alzheimer's Institute, Phoenix, AZ, USA.
Mayo Clinic in Arizona · USAlzheimer's Association · USBanner Alzheimer’s InstituteArizona Alzheimer’s ConsortiumUniversity of Arizona · US

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 1999 to 2018
$36.9M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
PET, APOE & the Preclinical Course of Alzheimer's DiseaseR01AG031581 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI CASELLI, RICHARD J., REIMAN, ERIC MICHAEL · 2008 to 2018
$16.6M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
NIA NIH HHS P30 AG019610NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG031581NIA NIH HHS R01 AG041851NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786NIH HHS
6 · The paper itself

Abstract

introductionWe previously characterized associations between brain imaging measurements of amyloid-β (Aβ) plaque burden and apolipoprotein E (APOE) ε4 gene dose in a small number of cognitively unimpaired late-middle-aged APOE ε4 homozygotes (HMs), heterozygotes (HTs), and noncarriers (NCs). We now characterize cross-sectional Aβ plaque, tau tangle, and cortical atrophy (neurodegeneration) measurements, classifications, and associations with age in a larger number of unimpaired HMs, HTs, and NCs over a wider age range.

methodsWe analyzed

resultsAβ PET measurements rose, plateaued at the respective ages of 68 and 76, and then declined with age in unimpaired HM and HT groups. Compared with NCs, these two groups began to have significantly higher Aβ PET measurements at ages 62 and 70, respectively, and no longer had significantly higher measurements by ages 71 and 78, respectively. They began to have significantly higher entorhinal cortex tau PET measurements at ages 66 and 70, respectively, and no longer had significantly higher measurements by ages 74 and 78, respectively. Brain atrophy measurements tended to decline slowly with age in all three genetic groups. Their elevated tau PET measurements were attributable to those with positive Aβ PET scans. 41.0%, 18.0%, and 5.0% of the 47- to 70-year-old HMs, HTs, and NCs and 25.0%, 79.0%, and 38.0% of the 71- to 86-year-old HMs, HTs, and NCs had positive Aβ PET scans, and the long-term recall memory scores are significantly higher in the older HMs than in HT and NC groups, suggesting resistance to Aβ deposition in those HMs who remained unimpaired at older ages.

conclusionsThis study provides information about Aβ plaque burden, tau tangle burden, and neurodegeneration in cognitively unimpaired persons at three levels of genetic risk for AD. Unimpaired APOE ε4 HMs can be studied before their 70s to evaluate the understanding of factors, processes, and interventions involved in the predisposition to and prevention of AD, and after their 70s, to discover factors, processes, and interventions involved in the resilience or resistance to and prevention of AD.

Indexed as

NeuroimagingAgedAllelesAmyloidApolipoprotein E4BrainCognitionCross-Sectional StudiesFemaleHealthy VolunteersHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedNeuropsychological TestsAmyloidApolipoprotein E4tau ProteinsAlzheimer'sAmyloidAPOEBiomarkersMRINeurodegenerationPETPreventionTau

Identifiers

PMID31831374
PMCPMC7187298
OpenAlexW2996615980

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.